<DOC>
	<DOCNO>NCT01775124</DOCNO>
	<brief_summary>The study evaluate efficacy safety two different dose regimen ranibizumab ( either monthly injection injection as-needed base stability patient 's vision ) Chinese patient wet AMD . This study provide long-term safety data treatment Chinese patient wet AMD .</brief_summary>
	<brief_title>Efficacy Safety Ranibizumab 0.5 mg Administered Two Alternative Dosing Regimens Chinese Patients With nAMD ( Age Related Macular Degeneration )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion criterion : Patients visual impairment due neovascular AMD A qualify vision score study entry Exclusion criterion Active infection inflammation either eye study entry Uncontrolled glaucoma either eye Any disorder study eye may affect vision Use systemic antiVEGFdrugs within 3 month prior study entry Previous treatment study eye wet AMD Any surgery study eye 3 month prior plan 6 month study entry Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>